Currently, GSK3β inhibitors have been proposed as possible neuroprotective drugs for the treatment of retinitis pigmentosa [11]; as modulators of cytosolic accumulation of TDP-43 during the cellular stress [12]; as a potential treatment for Parkinson’s disease [13]; as regulators of Th1 cells in EAE mice model [14] or as a neurorepair treatment in MS [15]. The gene discussed is GSK3B; the disease is myeloid sarcoma.